Skip to main content
Caplight Logo









Avirmax, Inc.

Avirmax, Inc.

Private
Hayward, CaliforniaHealthcare & Life Scienceshttps://avirmax.com/

Last Round

Series A

Nov 12, 2019

Total Funding Raised

$3M

Company Overview

Avirmax, Inc. is a biotechnology company that develops AAV-mediated gene therapies for ocular diseases and provides contract development and manufacturing (CDMO) services for viral vectors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

adeno-associated virusAAVcontract development and manufacturing organizationCDMOgene therapyAAV vector manufacturingbioprocess developmentcGMP manufacturingcapsid engineeringplasmid DNA servicesviral vector productionocular gene therapybiotech manufacturinganalytical testingbiopharma outsourcing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Avirmax, Inc. Comparables

Compare Avirmax, Inc. with similar companies based on industry and business-model similarity.

Avirmax, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ascend Advanced Therapies
85%
PackGene Biotech
84%
VectorBuilder
76%

Avirmax, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 12, 2019

Key People

Founding team and executive leadership

Shengjiang Liu

President and CEO

Executive Team

Avirmax, Inc. Investors

Notable investors and investment history

Avirmax, Inc. investors
InvestorRounds
Bencao CapitalSeries A
Kaitai CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 12, 2019

    $3M round with Bencao Capital and Kaitai Capital.

Avirmax, Inc. Filings

Explore SEC and related filing metadata, where available.

Avirmax, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Avirmax, Inc.'s valuation, stock price, and market status.

Is Avirmax, Inc. a public or private company?

Avirmax, Inc. is a private company.

What is the current stock price of Avirmax, Inc.?

Avirmax, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Avirmax, Inc. worth (valuation)?

Valuation information for Avirmax, Inc. is not publicly available.

Can I buy Avirmax, Inc. stock?

Avirmax, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Avirmax, Inc.'s last funding round?

Avirmax, Inc.'s most recent funding round was Series A on November 12, 2019.

Who are the main investors in Avirmax, Inc.?

Key investors in Avirmax, Inc. include Bencao Capital, Kaitai Capital.

Will Avirmax, Inc. IPO soon?

No public IPO plans have been announced for Avirmax, Inc..

How can I track Avirmax, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Avirmax, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHayward, California
Employee Range10
Year Founded2019
Last FundingNov 12, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?